I.V. Labetalol during coronary artery surgery.
The hemodynamic effects of a fixed dose of 10 mg i.v. Labetalol were evaluated in 9 CAD patients during a surgical procedure for myocardial revascularisation. The results show a significant mean decrease in heart rate (HR) (-13%), systolic blood pressure (SBP) (-16%) and rate pressure product (RPP) (-28%). Other hemodynamic parameters were not significantly affected. These results were confirmed by a clinical study where in a series of 110 CAD patients 21 were treated during the surgical procedure with incremental doses of Labetalol to control high systolic blood pressure and tachycardia. Administration of a mean dose of 24.3 mg of Labetalol resulted in a significant decrease of RPP (-38%). No side effects related to Labetalol were encountered.
D000368:Aged; D001794:Blood Pressure / Q000187:drug effects*; D003327:Coronary Disease / Q000601:surgery*; D004983:Ethanolamines / Q000494:pharmacology*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007263:Infusions, Parenteral; D007741:Labetalol / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects
D004983:Ethanolamines; D007741:Labetalol